Eight patients discontinued telaprevir treatment early due to toxicity (mostly due to rashes); one patient required hospitalization due to progressive maculopapular rash, and another developed severe anemia (Hb ≤8 g/dL). This evidence concerns the gene GSTM1 and anemia.